Claims
- 1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
(a) a nucleotide sequence encoding the PTH1R receptor having the complete amino acid sequence at positions from about 1 to about 536 in SEQ ID NO:2; (b) a nucleotide sequence encoding the PTH1R receptor having the amino acid sequence at positions from about 2 to about 536 in SEQ ID NO:2; (c) a nucleotide sequence encoding the mature PTH1R receptor having the amino acid sequence at positions from about 25 to about 536 in SEQ ID NO:2; (d) a nucleotide sequence encoding the PTH1R receptor having the complete amino acid sequence encoded by the cDNA clone deposited with the ATCC as patent deposit PTA-916; (e) a nucleotide sequence encoding the mature PTH1R receptor having the amino acid sequence encoded by the cDNA deposited with the ATCC as patent deposit PTA-916; (f) a nucleotide sequence encoding the PTH1R extracellular domain; (g) a nucleotide sequence encoding the PTH1R transmembrane domain; and (h) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f) or (g).
- 2. The nucleic acid molecule of claim 1 wherein said polynucleotide has the complete nucleotide sequence in FIG. 1C (SEQ ID NO:1).
- 3. The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence in FIG. 1C (SEQ ID NO:1) encoding the PTH1R receptor having the complete amino acid sequence in FIG. 2A (SEQ ID NO:2).
- 4. The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence in FIG. 1C (SEQ ID NO: 1) encoding the mature PTH1R receptor having the amino acid sequence in FIG. 2A (SEQ ID NO:2).
- 5. The nucleic acid molecule of claim 1 wherein said polynucleotide has the complete nucleotide sequence of the cDNA clone deposited with the ATCC as patent deposit PTA-916.
- 6. The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence encoding the PTH1R receptor having the complete amino acid sequence encoded by the cDNA deposited with the ATCC as patent deposit PTA-916.
- 7. The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence encoding the mature PTH1R receptor having the amino acid sequence encoded by the cDNA clone deposited with the ATCC as patent deposit PTA-916.
- 8. An isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide having a nucleotide sequence identical to a nucleotide sequence in (a), (b), (c), (d), (e), (f) or (g) of claim 1 wherein said polynucleotide which hybridizes does not hybridize under stringent hybridization conditions to a polynucleotide having a nucleotide sequence consisting of only A residues or of only T residues.
- 9. An isolated nucleic acid molecule comprising a polynucleotide which encodes the amino acid sequence of an epitope-bearing portion of a PTH1R receptor having an amino acid sequence in (a), (b), (c), (d), (e), (f) or (g) of claim 1.
- 10. The isolated nucleic acid molecule of claim 1, which encodes the PTH1R receptor extracellular domain.
- 11. The isolated nucleic acid molecule of claim 1, which encodes the PTH 1R receptor transmembrane domain.
- 12. A method for making a recombinant vector comprising inserting an isolated nucleic acid molecule of claim 1 into a vector.
- 13. A recombinant vector produced by the method of claim 12.
- 14. A method of making a recombinant host cell comprising introducing the recombinant vector of claim 13 into a host cell.
- 15. A recombinant host cell produced by the method of claim 14.
- 16. A recombinant method for producing a PTH1R polypeptide, comprising culturing the recombinant host cell of claim 15 under conditions such that said polypeptide is expressed and recovering said polypeptide.
- 17. An isolated PTH1R polypeptide having an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
(a) the amino acid sequence of the PTH1R polypeptide having the complete amino acid sequence at positions from about 1 to about 536 in SEQ ID NO:2; (b) the amino acid sequence of the PTH1R polypeptide having the amino acid sequence at positions from about 2 to about 536 in SEQ ID NO:2; (c) the amino acid sequence of the mature PTH1R polypeptide having the amino acid sequence at positions from about 25 to about 536 in SEQ ID NO:2; (d) the amino acid sequence of the PTH1R polypeptide having the complete amino acid sequence encoded by the cDNA clone deposited with the ATCC as patent deposit PTA-916; (e) the amino acid sequence of the mature PTH1R polypeptide having the amino acid sequence encoded by the cDNA clone deposited with the ATCC as patent deposit PTA-916; (f) the amino acid sequence of the PTH1R receptor extracellular domain; (g) the amino acid sequence of the PTH1R receptor transmembrane domain; and (h) the amino acid sequence of an epitope-bearing portion of any one of the polypeptides of (a), (b), (c), (d), (e), (f), or (g).
- 18. An isolated polypeptide comprising an epitope-bearing portion of the PTH1R receptor protein.
- 19. An isolated antibody that binds specifically to a PTH1R receptor polypeptide of claim 17.
- 20. A method of treating diseases and disorders associated with the decreased PTH1R activity comprising administering an effective amount of the polypeptide as claimed in claim 17, or an agonist thereof to a patient in need thereof.
- 21. A method of treating diseases and disorders associated with increased PTH1R activity comprising administering an effective amount an antagonist of the polypeptide as claimed in claim 17 to a patient in need thereof.
- 22. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
(a) a nucleotide sequence encoding the PTH3R receptor having the complete amino acid sequence at positions from about 1 to about 542 in (SEQ ID NO:4); (b) a nucleotide sequence encoding the PTH3R receptor having the amino acid sequence at positions from about 2 to about 542 in (SEQ ID NO:4); (c) a nucleotide sequence encoding the mature PTH3R receptor having the amino acid sequence at positions from about 22 to about 542 in (SEQ ID NO:4); (d) a nucleotide sequence encoding the PTH3R receptor having the complete amino acid sequence encoded by the cDNA clone deposited with the ATCC as patent deposit PTA-915; (e) a nucleotide sequence encoding the mature PTH3R receptor having the amino acid sequence encoded by the cDNA clone deposited with the ATCC as patent deposit PTA-915; (f) a nucleotide sequence encoding the PTH3R extracellular domain; (g) a nucleotide sequence encoding the PTH3R transmembrane domain; (h) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f) or (g).
- 23. The nucleic acid molecule of claim 22 wherein said polynucleotide has the complete nucleotide sequence in FIG. 1D (SEQ ID NO:3).
- 24. The nucleic acid molecule of claim 22 wherein said polynucleotide has the nucleotide sequence in FIG. 1D (SEQ ID NO:3) encoding the PTH3R receptor having the complete amino acid sequence in FIG. 2B (SEQ ID NO:4).
- 25. The nucleic acid molecule of claim 22 wherein said polynucleotide has the nucleotide sequence in FIG. 1D (SEQ ID NO:3) encoding the mature PTH3R receptor having the amino acid sequence in FIG. 2B (SEQ ID NO:4).
- 26. The nucleic acid molecule of claim 22 wherein said polynucleotide has the complete nucleotide sequence of the cDNA clone deposited with the ATCC as patent deposit PTA-915.
- 27. The nucleic acid molecule of claim 22 wherein said polynucleotide has the nucleotide sequence encoding the PTH3R receptor having the complete amino acid sequence encoded by the cDNA clone deposited with the ATCC as patent deposit PTA-915.
- 28. The nucleic acid molecule of claim 22 wherein said polynucleotide has the nucleotide sequence encoding the mature PTH3R receptor having the amino acid sequence encoded by the cDNA clone deposited with the ATCC as patent deposit PTA-915.
- 29. An isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide having a nucleotide sequence identical to a nucleotide sequence in (a), (b), (c), (d), (e), (f), (g), or (h) of claim 22 wherein said polynucleotide which hybridizes does not hybridize under stringent hybridization conditions to a polynucleotide having a nucleotide sequence consisting of only A residues or of only T residues.
- 30. An isolated nucleic acid molecule comprising a polynucleotide which encodes the amino acid sequence of an epitope-bearing portion of a PTH3R receptor having an amino acid sequence in (a), (b), (c), (d), (e), (f), (g), or (h) of claim 22.
- 31. The isolated nucleic acid molecule of claim 22, which encodes the PTH3R receptor extracellular domain.
- 32. The isolated nucleic acid molecule of claim 22, which encodes the PTH3R receptor transmembrane domain.
- 33. A method for making a recombinant vector comprising inserting an isolated nucleic acid molecule of claim 22 into a vector.
- 34. A recombinant vector produced by the method of claim 33.
- 35. A method of making a recombinant host cell comprising introducing the recombinant vector of claim 34 into a host cell.
- 36. A recombinant host cell produced by the method of claim 35.
- 37. A recombinant method for producing a PTH3R polypeptide, comprising culturing the recombinant host cell of claim 36 under conditions such that said polypeptide is expressed and recovering said polypeptide.
- 38. An isolated PTH3R polypeptide having an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
(a) the amino acid sequence of the PTH3R polypeptide having the complete amino acid sequence at positions from about 1 to about 542 in (SEQ ID NO:4); (b) the amino acid sequence of the PTH3R polypeptide having the amino acid sequence at positions from about 2 to about 542 in (SEQ ID NO:4); (c) the amino acid sequence of the mature PTH3R polypeptide having the amino acid sequence at positions from about 22 to about 542 in(SEQ ID NO:4); (d) the amino acid sequence of the PTH3R polypeptide having the complete amino acid sequence encoded by the cDNA clone deposited with the ATCC as patent deposit PTA-915; (e) the amino acid sequence of the mature PTH3R polypeptide having the amino acid sequence encoded by the cDNA clone deposited with the ATCC as patent deposit PTA-915; (f) the amino acid sequence of the PTH3R receptor extracellular domain; (g) the amino acid sequence of the PTH3R receptor transmembrane domain; (h) the amino acid sequence of an epitope-bearing portion of any one of the polypeptides of (a), (b), (c), (d), (e), (f), or (g).
- 39. An isolated polypeptide comprising an epitope-bearing portion of the PTH3R receptor protein.
- 40. An isolated antibody that binds specifically to a PTH3R receptor polypeptide of claim 38
- 41. A method of treating diseases and disorders associated with the decreased PTH3R activity comprising administering an effective amount of the polypeptide as claimed in claim 38, or an agonist thereof to a patient in need thereof.
- 42. A method of treating diseases and disorders associated with increased PTH3R activity comprising administering an effective amount an antagonist of the polypeptide as claimed in claim 38 to a patient in need thereof.
- 43. An isolated polynucleotide encoding a modified PTH3R protein, wherein, except for at least one conservative amino acid substitution, said modified protein has an amino acid sequence that is identical to a member selected from the group consisting of:
(a) amino acids 1 to 542 of SEQ ID NO:4; (b) amino acids 2 to 542 of SEQ ID NO:4; and (c) amino acids 22 to 542 of SEQ ID NO:4.
- 44. A modified PTH3R protein, wherein, except for at least one conservative amino acid substitution, said modified protein has an amino acid sequence that is identical to a member selected from the group consisting of:
(a) amino acids 1 to 542 of SEQ ID NO:4; (b) amino acids 2 to 542 of SEQ ID NO:4; and (c) amino acids 22 to 542 of SEQ ID NO:4.
- 45. An isolated polynucleotide encoding a modified PTH1R protein, wherein, except for at least one conservative amino acid substitution, said modified protein has an amino acid sequence that is identical to a member selected from the group consisting of:
(a) amino acids 1 to 536 of SEQ ID NO:2; (b) amino acids 2 to 536 of SEQ ID NO:2; and (c) amino acids 25 to 536 of SEQ ID NO:2.
- 46. A modified PTH1R protein, wherein, except for at least one conservative amino acid substitution, said modified protein has an amino acid sequence that is identical to a member selected from the group consisting of:
(a) amino acids 1 to 536 of SEQ ID NO:2; (b) amino acids 2 to 536 of SEQ ID NO:2; and (c) amino acids 25 to 536 of SEQ ID NO:2.
- 47. A method for the isolation of a nucleic acid molecule comprising
(a) selecting a fragment of SEQ ID NO:3 as a nucleic acid probe; (b) hybridizing said probe overnight to at least one test sequence by incubation at 42° C. in a solution of 30% formamide, 5×SSC (150 mM NaCI, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5×Denhardt's solution, 10% dextran sulfate, and 20 g/ml denatured, sheared salmon sperm DNA; and (c) removing nonhydridized probe by washing with a solution of 2×SSC or 1×SSC or 0.5×SSC at about 55° C. or 60° C. or 65° C.; (d) identifying a target sequence bound by said probe;
wherein said identified target sequence is at least about 70% identical to a sequence selected from the group consisting of:
(e) a nucleotide sequence encoding the PTH3 R receptor having the complete amino acid sequence at positions from about 1 to about 523 in (SEQ ID NO:4); (f) a nucleotide sequence encoding the PTH3 R receptor having the amino acid sequence at positions from about 2 to about 523 in (SEQ ID NO:4); (g) a nucleotide sequence encoding the mature PTH3R receptor having the amino acid sequence at positions from about 22 to about 523 in (SEQ ID NO:4); (h) a nucleotide sequence encoding the PTH3 R receptor having the complete amino acid sequence encoded by the cDNA clone deposited with the ATCC as patent deposit PTA-915; (i) a nucleotide sequence encoding the mature PTH3R receptor having the amino acid sequence encoded by the cDNA clone deposited with the ATCC as patent deposit PTA-915; (j) a nucleotide sequence encoding the PTH3R extracellular domain; (k) a nucleotide sequence encoding the PTH3R transmembrane domain; (l) a nucleotide sequence complementary to any of the nucleotide sequences in (e), (f), (g), (h), (i), (j) or (k).
Parent Case Info
[0001] This application claims the benefit of the filing date of provisional application No. 60/110,467 filed on Nov. 30, 1998, which is herein incorporated by reference.
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY-SPONSORED RESEARCH AND DEVELOPMENT
[0002] Part of the work performed during development of this invention utilized U.S. Government funds. The U.S. Government has certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60110467 |
Nov 1998 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09449632 |
Nov 1999 |
US |
Child |
10372095 |
Feb 2003 |
US |